Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells.
机构:[1]Wuhan Institutes of Biomedical Sciences, School of Medicine, JianghanUniversity, Wuhan 430056, China[2]Guangdong Provincial Key Laboratoryof Liver Disease Research, The Third Affiliated Hospital, Sun Yat-sen University,Guangzhou 510620, China中山大学附属第三医院[3]Zhuhai Interventional Medical Center, ZhuhaiPrecision Medical Center, Zhuhai People’s Hospital, Zhuhai Hospital Affiliatedwith Jinan University, Zhuhai 519000, China[4]Jiangsu Key Laboratory of DrugScreening, Jiangsu Center for Pharmacodynamics Research and Evaluation,China Pharmaceutical University, Nanjing 2100 9, China[5]School of Pharmacy,Hubei University of Chinese Medicine, Wuhan 430065, China
第一作者机构:[1]Wuhan Institutes of Biomedical Sciences, School of Medicine, JianghanUniversity, Wuhan 430056, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Hou Xiaoying,Du Cong,Lu Ligong,et al.Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells.[J].WORLD JOURNAL OF SURGICAL ONCOLOGY.2022,20(1):doi:10.1186/s12957-022-02510-8.
APA:
Hou Xiaoying,Du Cong,Lu Ligong,Yuan Shengtao,Zhan Meixiao...&Du Hongzhi.(2022).Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells..WORLD JOURNAL OF SURGICAL ONCOLOGY,20,(1)
MLA:
Hou Xiaoying,et al."Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells.".WORLD JOURNAL OF SURGICAL ONCOLOGY 20..1(2022)